Back to Search

A Phase 1, Open-label, Dose Finding Study of CC-90009, a Novel Cereblon E3 Ligase Modulating Drug, in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes

  • Protocol Number: 201605064
  • Principal Investigator: Uy, Geoffrey
  • Cancer Types: Leukemia, Myeloma, and Hematologic

For more information on this trial, contact us here:


Brief Summary

Protocol Interventions